Xenetic Biosciences PE Ratio 2013-2025 | XBIO

Current and historical p/e ratio for Xenetic Biosciences (XBIO) from 2013 to 2025. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Xenetic Biosciences PE ratio as of January 13, 2026 is 0.00.
Xenetic Biosciences PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2026-01-13 2.21 0.00
2025-09-30 3.14 $-2.05 0.00
2025-06-30 3.92 $-2.00 0.00
2025-03-31 2.61 $-2.38 0.00
2024-12-31 3.99 $-2.57 0.00
2024-09-30 4.32 $-2.66 0.00
2024-06-30 4.07 $-3.07 0.00
2024-03-31 3.77 $-2.93 0.00
2023-12-31 3.45 $-2.75 0.00
2023-09-30 4.90 $-2.98 0.00
2023-06-30 3.28 $-2.89 0.00
2023-03-31 4.06 $-4.10 0.00
2022-12-31 2.85 $-4.70 0.00
2022-09-30 5.37 $-3.70 0.00
2022-06-30 8.01 $-4.40 0.00
2022-03-31 10.20 $-3.80 0.00
2021-12-31 12.90 $-4.10 0.00
2021-09-30 20.50 $-5.60 0.00
2021-06-30 20.40 $-16.30 0.00
2021-03-31 21.80 $-16.50 0.00
2020-12-31 20.40 $-16.90 0.00
2020-09-30 9.05 $-15.40 0.00
2020-06-30 10.20 $-30.10 0.00
2020-03-31 7.41 $-44.20 0.00
2019-12-31 14.40 $-107.13 0.00
2019-09-30 11.97 $-127.53 0.00
2019-06-30 112.50 $-123.64 0.00
2019-03-31 232.80 $-135.65 0.00
2018-12-31 196.80 $-96.04 0.00
2018-09-30 339.60 $-14.41 0.00
2018-06-30 489.60 $-22.81 0.00
2018-03-31 258.00 $-36.01 0.00
2017-12-31 230.22 $-51.62 0.00
2017-09-30 242.40 $-148.86 0.00
2017-06-30 331.20 $-151.26 0.00
2017-03-31 546.00 $-845.14 0.00
2016-12-31 516.00 $-883.56 0.00
2016-09-30 540.00 $-847.55 0.00
2016-06-30 612.00 $-813.93 0.00
2016-03-31 1207.68 $-79.24 0.00
2015-12-31 2019.40 0 0.00
2015-09-30 1405.66 0 0.00
2015-06-30 736.49 0 0.00
2015-03-31 811.72 0 0.00
2014-12-31 989.90 0 0.00
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $0.005B $0.003B
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. Additionally, Xenetic is leveraging PolyXen(TM), its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen(TM) has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and expects to earn royalty payments under this agreement.
Stock Name Country Market Cap PE Ratio
Chugai Pharmaceutical (CHGCY) Japan $87.245B 33.14
Zoetis (ZTS) United States $54.919B 19.66
Takeda Pharmaceutical (TAK) Japan $50.943B 10.40
Daiichi Sankyo, - (DSNKY) Japan $42.301B 21.07
BeOne Medicines - (ONC) Switzerland $38.498B 204.10
Sandoz Group AG (SDZNY) Switzerland $32.476B 0.00
United Therapeutics (UTHR) United States $20.532B 18.07
Merck (MKKGY) Germany $19.360B 11.94
Shionogi (SGIOY) Japan $15.432B 14.17
Neurocrine Biosciences (NBIX) United States $13.187B 31.64
Summit Therapeutics (SMMT) United States $12.963B 0.00
Ionis Pharmaceuticals (IONS) United States $12.874B 0.00
IPSEN (IPSEY) France $12.596B 0.00
Madrigal Pharmaceuticals (MDGL) United States $11.217B 0.00
Orion OYJ (ORINY) Finland $10.204B 29.15
Eisai (ESAIY) $8.586B 0.00
Ono Pharmaceutical (OPHLF) Japan $6.576B 20.00
Stevanato Group S.p.A (STVN) Italy $6.178B 34.58
Grifols, S.A (GRFS) Spain $6.078B 0.00
Crinetics Pharmaceuticals (CRNX) United States $5.154B 0.00
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $4.613B 0.00
Indivior (INDV) United States $4.251B 17.35
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $4.077B 19.36
Corcept Therapeutics (CORT) United States $3.824B 41.31
NewAmsterdam Pharma (NAMS) Netherlands $3.613B 0.00
Centessa Pharmaceuticals (CNTA) United Kingdom $2.987B 0.00
Hypermarcas (HYPMY) Brazil $2.784B 19.11
Catalyst Pharmaceuticals (CPRX) United States $2.747B 8.76
Dyne Therapeutics (DYN) United States $2.434B 0.00
Soleno Therapeutics (SLNO) United States $2.230B 0.00
Ocular Therapeutix (OCUL) United States $2.222B 0.00
Avadel Pharmaceuticals (AVDL) Ireland $2.098B 0.00
Guardian Pharmacy Services (GRDN) United States $1.979B 38.12
Aurinia Pharmaceuticals Inc (AUPH) Canada $1.976B 23.42
Harrow (HROW) United States $1.748B 107.25
Ardelyx (ARDX) United States $1.711B 0.00
Enliven Therapeutics (ELVN) United States $1.528B 0.00
Oruka Therapeutics (ORKA) United States $1.517B 0.00
Collegium Pharmaceutical (COLL) United States $1.495B 7.40
BioCryst Pharmaceuticals (BCRX) United States $1.422B 84.38
Amylyx Pharmaceuticals (AMLX) United States $1.384B 0.00
Relay Therapeutics (RLAY) United States $1.376B 0.00
Evotec AG (EVO) Germany $1.374B 0.00
Xeris Biopharma Holdings (XERS) United States $1.279B 0.00
Savara (SVRA) United States $1.205B 0.00
ARS Pharmaceuticals (SPRY) United States $1.118B 0.00
Cronos Group (CRON) Canada $1.032B 0.00
Theravance Biopharma (TBPH) United States $1.030B 43.26
Xencor (XNCR) United States $0.995B 0.00
Esperion Therapeutics (ESPR) United States $0.789B 0.00
KalVista Pharmaceuticals (KALV) United States $0.755B 0.00
Ironwood Pharmaceuticals (IRWD) United States $0.755B 17.85
Nektar Therapeutics (NKTR) United States $0.744B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.689B 6.15
ProKidney (PROK) United States $0.689B 0.00
Bioventus (BVS) United States $0.637B 13.05
Lexeo Therapeutics (LXEO) United States $0.542B 0.00
Organogenesis (ORGO) United States $0.518B 0.00
Elite Pharmaceuticals (ELTP) United States $0.516B 0.00
Lyell Immunopharma (LYEL) United States $0.504B 0.00
Zevra Therapeutics (ZVRA) United States $0.502B 0.00
Siga Technologies (SIGA) United States $0.473B 6.47
4D Molecular Therapeutics (FDMT) United States $0.449B 0.00
Altimmune (ALT) United States $0.418B 0.00
Aquestive Therapeutics (AQST) United States $0.417B 0.00
Nature's Sunshine Products (NATR) United States $0.392B 23.34
USANA Health Sciences (USNA) United States $0.371B 10.36
Akebia Therapeutics (AKBA) United States $0.366B 0.00
Avalo Therapeutics (AVTX) United States $0.318B 0.00
Profound Medical (PROF) Canada $0.304B 0.00
Relmada Therapeutics (RLMD) United States $0.298B 0.00
Achieve Life Sciences (ACHV) Canada $0.294B 0.00
Aclaris Therapeutics (ACRS) United States $0.294B 0.00
Silence Therapeutics (SLN) United Kingdom $0.279B 0.00
Larimar Therapeutics (LRMR) United States $0.276B 0.00
Fractyl Health (GUTS) United States $0.275B 0.00
OmniAb (OABI) United States $0.274B 0.00
Heron Therapeutics (HRTX) United States $0.271B 0.00
Protara Therapeutics (TARA) United States $0.254B 0.00
Aldeyra Therapeutics (ALDX) United States $0.249B 0.00
Journey Medical (DERM) United States $0.217B 0.00
Enlivex Therapeutics (ENLV) Israel $0.210B 0.00
Galectin Therapeutics (GALT) United States $0.198B 0.00
Tonix Pharmaceuticals Holding (TNXP) United States $0.190B 0.00
Century Therapeutics (IPSC) United States $0.188B 0.00
Minerva Neurosciences (NERV) United States $0.185B 0.00
MediWound (MDWD) Israel $0.183B 0.00
Innate Pharma SA (IPHYF) France $0.181B 0.00
Surrozen (SRZN) United States $0.177B 0.00
AleAnna (ANNA) United States $0.168B 0.00
Procaps Group, S.A (PROCF) Luxembourg $0.161B 0.00
Karyopharm Therapeutics (KPTI) United States $0.145B 0.00
Prelude Therapeutics (PRLD) United States $0.141B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.139B 0.00
Context Therapeutics (CNTX) United States $0.138B 0.00
Incannex Healthcare (IXHL) Australia $0.132B 0.00
Unicycive Therapeutics (UNCY) United States $0.130B 0.00
Verrica Pharmaceuticals (VRCA) United States $0.128B 0.00
VAXART, INC (VXRT) United States $0.127B 0.00
Inhibikase Therapeutics (IKT) United States $0.126B 0.00
Pyxis Oncology (PYXS) United States $0.117B 0.00
Avita Medical (RCEL) United States $0.101B 0.00
Cassava Sciences (SAVA) United States $0.099B 0.00
Champions Oncology (CSBR) United States $0.098B 41.50
Cardiol Therapeutics (CRDL) Canada $0.097B 0.00
Vivani Medical (VANI) United States $0.093B 0.00
Gain Therapeutics (GANX) United States $0.086B 0.00
Korro Bio (KRRO) United States $0.085B 0.00
PolyPid (PYPD) Israel $0.070B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.070B 58.50
Dominari Holdings (DOMH) United States $0.068B 0.00
Assertio Holdings (ASRT) United States $0.066B 0.00
Plus Therapeutics (PSTV) United States $0.065B 0.00
Arch Biopartners (ACHFF) Canada $0.065B 0.00
Metagenomi (MGX) United States $0.065B 0.00
Rafael Holdings (RFL) United States $0.064B 0.00
NRx Pharmaceuticals (NRXP) United States $0.063B 0.00
PMV Pharmaceuticals (PMVP) United States $0.062B 0.00
Lipocine (LPCN) United States $0.058B 0.00
Lite Strategy (LITS) United States $0.055B 0.00
Acrivon Therapeutics (ACRV) United States $0.054B 0.00
Nutriband (NTRB) United States $0.052B 0.00
ElectroCore (ECOR) United States $0.050B 0.00
Talphera (TLPH) United States $0.048B 0.00
Telomir Pharmaceuticals (TELO) United States $0.046B 0.00
Reviva Pharmaceuticals Holdings (RVPH) United States $0.041B 0.00
FibroGen (FGEN) United States $0.039B 0.00
Wellgistics Health (WGRX) United States $0.038B 0.00
FibroGen (KYNB) United States $0.037B 0.00
Mural Oncology (MURA) Ireland $0.035B 0.00
Jupiter Neurosciences (JUNS) United States $0.032B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.029B 0.00
Natural Alternatives (NAII) United States $0.028B 0.00
SCYNEXIS (SCYX) United States $0.028B 0.00
TherapeuticsMD (TXMD) United States $0.024B 0.00
Klotho Neurosciences (KLTO) United States $0.024B 0.00
Scienture Holdings (SCNX) United States $0.022B 0.00
Inotiv (NOTV) United States $0.021B 0.00
Liminatus Pharma (LIMN) United States $0.021B 0.00
VYNE Therapeutics (VYNE) United States $0.019B 0.00
Iterum Therapeutics (ITRM) Ireland $0.018B 0.00
Citius Pharmaceuticals (CTXR) United States $0.018B 0.00
Vyome Holdings (HIND) United States $0.018B 0.00
Vivos Therapeutics (VVOS) United States $0.018B 0.00
Cosmos Health (COSM) United States $0.018B 0.00
Mannatech (MTEX) United States $0.014B 0.00
Tempest Therapeutics (TPST) United States $0.013B 0.00
Traws Pharma (TRAW) United States $0.013B 0.02
CASI Pharmaceuticals (CASI) China $0.013B 0.00
Phio Pharmaceuticals (PHIO) United States $0.013B 0.00
BioLineRx (BLRX) Israel $0.012B 0.00
China SXT Pharmaceuticals (SXTC) China $0.012B 0.00
Addex Therapeutics (ADXN) Switzerland $0.011B 0.00
Curanex Pharmaceuticals Inc (CURX) United States $0.010B 0.00
Mangoceuticals (MGRX) United States $0.010B 0.00
Ernexa Therapeutics (ERNA) United States $0.010B 0.00
BioVie (BIVI) United States $0.010B 0.00
XTL Biopharmaceuticals (XTLB) Israel $0.009B 0.00
Nuvilex (PMCB) United States $0.009B 0.00
Ainos (AIMD) United States $0.009B 0.00
Quoin Pharmaceuticals (QNRX) United States $0.009B 0.00
Kiora Pharmaceuticals (KPRX) United States $0.008B 0.00
Biomerica (BMRA) United States $0.008B 0.00
Salarius Pharmaceuticals (DCOY) United States $0.008B 0.00
TransCode Therapeutics (RNAZ) United States $0.008B 0.00
Heatwurx (PCSA) United States $0.007B 0.00
Aptorum Group (APM) United Kingdom $0.007B 0.00
Indaptus Therapeutics (INDP) United States $0.006B 0.00
Redhill Biopharma (RDHL) Israel $0.006B 0.00
Alaunos Therapeutics (TCRT) United States $0.006B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.006B 0.00
Salarius Pharmaceuticals (SLRX) United States $0.005B 0.00
XORTX Therapeutics (XRTX) Canada $0.004B 0.00
Clearmind Medicine (CMND) Canada $0.004B 0.00
Lyra Therapeutics (LYRA) United States $0.004B 0.00
InMed Pharmaceuticals (INM) Canada $0.003B 0.00
Jaguar Animal Health (JAGX) United States $0.003B 0.00
Universe Pharmaceuticals INC (UPC) China $0.002B 0.00
Shuttle Pharmaceuticals Holdings (SHPH) United States $0.002B 0.00
CDT Equity (CDT) United States $0.002B 0.00
60 Degrees Pharmaceuticals (SXTP) United States $0.002B 0.00
PainReform (PRFX) Israel $0.002B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.001B 0.00
SciSparc (SPRC) Israel $0.001B 0.00
Aditxt (ADTX) United States $0.001B 0.00
Emisphere Technologies (EMIS) United States $0.000B 0.00
4D Pharma (LBPS) United Kingdom $0.000B 0.00
Patheon (PTHN) Netherlands $0.000B 0.00
RVL Pharmaceuticals (RVLP) United States $0.000B 0.00